Inventor
FREIMOSER-GRUNDSCHOBER ANNE
CH25 patents
⚠️ This page may combine multiple inventors who share the name “FREIMOSER-GRUNDSCHOBER ANNE”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
ROCHE GLYCART AG
8 patentsUS10184009B2Jan 22, 2019
Mutant interleukin-2 polypeptides
ROCHE GLYCART AG37 citations97
US10577429B2Mar 3, 2020
Anti-FAP antibodies and methods of use
ROCHE GLYCART AG17 citations94
US10323098B2Jun 18, 2019
Mutant interleukin-2 polypeptides
ROCHE GLYCART AG25 citations94
US10253110B2Apr 9, 2019
Anti-FAP antibodies and methods of use
ROCHE GLYCART AG15 citations94
US11332545B2May 17, 2022
Anti-FAP antibodies and methods of use
ROCHE GLYCART AG6 citations86
US11111312B2Sep 7, 2021
Mutant interleukin-2 polypeptides
ROCHE GLYCART AG8 citations84
US12286486B2Apr 29, 2025
Anti-FAP antibodies and methods of use
ROCHE GLYCART AG0 citations62
US9994610B2Jun 12, 2018
Separation method for fucosylated antibodies
ROCHE GLYCART AG0 citations50
HOFFMANN LA ROCHE
8 patentsUS11780920B2Oct 10, 2023
Antibodies binding to CD3 and CD19
HOFFMANN LA ROCHE4 citations72
US11672858B2Jun 13, 2023
Bispecific antibody molecules binding to CD3 and TYRP-1
HOFFMANN LA ROCHE2 citations72
US11591397B2Feb 28, 2023
Bispecific antibody molecules binding to CD3 and EGFRvIII
HOFFMANN LA ROCHE2 citations72
US12215155B2Feb 4, 2025
Antibodies binding to CD3 and CD19
HOFFMANN LA ROCHE1 citations62
US12139553B2Nov 12, 2024
T cell activating bispecific antigen binding molecules
HOFFMANN LA ROCHE0 citations62
US12473373B2Nov 18, 2025
Bispecific antibody molecules binding to CD3 and EGFRvIII
HOFFMANN LA ROCHE0 citations61
US10882918B2Jan 5, 2021
Bispecific T cell activating antigen binding molecules
HOFFMANN LA ROCHE1 citations57
US12466889B2Nov 11, 2025
Anti-HLA-G antibodies and use thereof
HOFFMANN LA ROCHE0 citations44